EAACI Congress 2024: Innovation and Advances in Allergy Treatment

EAACI Congress 2024
EAACI Congress 2024

EAACI Congress 2024

  • Over 150 scientific sessions will be presented during the congress, focusing on advancements in environmental science, food allergies, innovations in immunotherapy, and pediatric allergies, among others.
  • Precision medicine, AI, immunotherapy, and immune modulators will converge at the largest allergy and immunology congress.
  • The congress will occur from 31 May to 3 June in Valencia, Spain.

VALENCIA, Spain, April 30, 2024 (GLOBE NEWSWIRE) — The European Academy of Allergy and Clinical Immunology (EAACI), an association comprising over 16,000 researchers and healthcare professionals from 125 countries, invites you to the annual congress at Feria Valencia, Spain, from 31 May to 3 June. Under the theme “Revolutionizing Patient Care through the Power of Data Science,” the EAACI Congress 2024 positions itself as the European event of the year, gathering the latest research and advancements in allergies and their treatment.

We firmly believe in the importance of your contribution to knowledge and its impact on improving patient care in allergy and asthma. As a healthcare professional or medical student at the congress, you will enrich your clinical practice and knowledge and contribute to advancing science and healthcare.

During the congress, you can participate in keynote lectures, plenary sessions, oral presentations, and poster sessions, all featuring cutting-edge research, clinical updates, and emerging therapies in allergy and asthma. Additionally, you will have the chance to connect with some of the most influential leaders in the field and engage in in-depth discussions on the latest advancements. The scientific program of the EAACI Congress 2024 will cover the entire spectrum of clinical allergy and immunology and will feature over 150 scientific sessions, including topics such as environmental science, food allergies, innovations in immunotherapy, and pediatric allergies, among others.

Please review the program and encourage your medical team, students, and professors to register for the EAACI Congress 2024. It will be an invaluable opportunity to continue learning, exchange ideas, and collaborate with other professionals in the field. We look forward to welcoming you to Valencia!

PROGRAM
https://eaaci.org/agenda/eaaci-congress-2024/

REGISTER
https://eaaci.org/events_congress/eaaci-congress-2024/registration/registration/

SOCIAL MEDIA
Podcast: https://linktr.ee/eaaci
LinkedIn: https://www.linkedin.com/company/eaaci/
Instagram: @eaaciHQ
Twitter: @EAACI_HQ
Facebook: https://www.facebook.com/EAACI

CONTACT
communications@eaaci.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dbb1a2e3-3aaf-442d-84ff-18369811d587

GlobeNewswire Distribution ID 1000947860″

Congresso da EAACI 2024: Inovação e Avanços no Tratamento da Alergia

EAACI Congress 2024
EAACI Congress 2024

EAACI Congress 2024

  • Durante o congresso serão apresentadas mais de 150 sessões científicas, centradas nos avanços da ciência ambiental, alergias alimentares, inovações em imunoterapia e alergias pediátricas, entre outras.
  • A medicina de precisão, a IA, a imunoterapia e os moduladores imunitários irão convergir no maior congresso de alergia e imunologia.
  • O congresso decorrerá de 31 de maio a 3 de junho em Valência, Espanha.

VALÊNCIA, Espanha, April 30, 2024 (GLOBE NEWSWIRE) — A Academia Europeia de Alergia e Imunologia Clínica (EAACI), uma associação que inclui mais de 16 000 investigadores e profissionais de saúde de 125 países, convida-o(a) para o congresso anual na Feria Valencia, em Espanha, de 31 de maio a 3 de junho. Sob o tema “Revolucionar os Cuidados de Saúde dos Doentes através do Poder da Ciência dos Dados,” o Congresso da EAACI 2024 posiciona-se como o evento europeu do ano, reunindo as mais recentes investigações e avanços nas alergias e no tratamento destas.

Acreditamos firmemente na importância da sua contribuição para o conhecimento e do seu impacto na melhoria do atendimento ao paciente em alergia e asma. Como profissional de saúde ou estudante de medicina no Congresso, irá enriquecer a sua prática clínica e conhecimento e contribuir para o avanço da ciência e da saúde.

Durante o congresso, poderá participar em palestras, sessões plenárias, apresentações com oradores e sessões de apresentação pública dos trabalhos, todas elas com investigação de ponta, atualizações clínicas e terapias emergentes em alergia e asma. Além disso, terá a oportunidade de contactar com alguns dos líderes mais influentes da área e participar em debates aprofundados sobre os mais recentes avanços. O programa científico do Congresso da EAACI 2024 abrangerá todo o espectro da alergia e imunologia clínicas e contará com mais de 150 sessões científicas, incluindo temas tais como a ciência ambiental, alergias alimentares, inovações em imunoterapia e alergias pediátricas, entre outros.

Consulte o programa e incentive a sua equipa médica, estudantes e professores a registarem-se no Congresso da EAACI 2024. Esta será uma oportunidade inestimável para continuar a aprender, trocar ideias e colaborar com outros profissionais da área. Estamos ansiosos por recebê-lo(a) em Valência!

PROGRAMA
https://eaaci.org/agenda/eaaci-congress-2024/

REGISTO
https://eaaci.org/events_congress/eaaci-congress-2024/registration/registration/

REDES SOCIAIS
Podcast: https://linktr.ee/eaaci
LinkedIn: https://www.linkedin.com/company/eaaci/
Instagram: @eaaciHQ
Twitter: @EAACI_HQ
Facebook: https://www.facebook.com/EAACI

CONTACTO
communications@eaaci.org

A fotografia que acompanha este anúncio está disponível em http://www.globenewswire.com/NewsRoom/AttachmentNg/dbb1a2e3-3aaf-442d-84ff-18369811d587

GlobeNewswire Distribution ID 1000947860

Congrès EAACI 2024 : innovations et progrès dans le traitement des allergies

EAACI Congress 2024
EAACI Congress 2024

EAACI Congress 2024

  • Lors de ce congrès, plus de 150 sessions scientifiques seront présentées. Les sujets abordés se concentreront sur les progrès de la science environnementale, les allergies alimentaires, les innovations en matière d’immunothérapie et les allergies pédiatriques, entre autres.
  • Les acteurs majeurs des domaines de la médecine de précision, de l’intelligence artificielle, de l’immunothérapie et des modulateurs immunitaires seront rassemblés lors du plus grand congrès d’allergie et d’immunologie.
  • Le congrès se tiendra du 31 mai au 3 juin prochains à Valence, en Espagne.

VALENCE, Espagne, 30 avr. 2024 (GLOBE NEWSWIRE) — L’Académie européenne d’allergie et d’immunologie clinique (EAACI), une association regroupant plus de 16 000 chercheurs et professionnels de la santé issus de 125 pays, vous invite à son congrès annuel qui se tiendra à Valence en Espagne du 31 mai au 3 juin prochains. Sous le thème « Révolutionner les soins aux patients grâce au pouvoir de la science des données », le Congrès EAACI 2024 se positionne comme l’événement européen de l’année qui permettra de réunir les dernières recherches et avancées dans le domaine des allergies et de leur traitement.

Nous sommes convaincus de l’importance de votre contribution à la connaissance et des retombées sur l’amélioration des soins aux patients pour l’allergie et l’asthme. Vous pourrez, grâce à votre participation à ce congrès en votre qualité de professionnel de la santé ou d’étudiant en médecine, enrichir votre pratique clinique et vos connaissances et contribuer à faire progresser la science et les soins de santé.

Vous aurez l’occasion de participer à des conférences, des séances plénières, des présentations orales et des sessions de présentation, qui porteront toutes sur la recherche de pointe, les mises à jour cliniques et les thérapies émergentes dans le domaine de l’allergie et de l’asthme. En outre, vous pourrez rencontrer certains des acteurs majeurs les plus influents dans le domaine et participer à des discussions approfondies sur les dernières avancées. Le programme scientifique du congrès EAACI 2024 couvrira l’ensemble du spectre de l’allergie et de l’immunologie cliniques. Plus de 150 sessions scientifiques seront proposées, abordant en autres des sujets tels que la science environnementale, les allergies alimentaires, les innovations en immunothérapie et les allergies pédiatriques.

Nous vous invitons à prendre connaissance du programme et encourager votre équipe médicale, vos étudiants et vos professeurs à s’inscrire au Congrès EAACI 2024. Ce congrès constituera une occasion inestimable de continuer à acquérir des connaissances, d’échanger et de partager des idées avec d’autres professionnels dans ce domaine. Nous sommes impatients de vous accueillir à Valence !

PROGRAMME :
https://eaaci.org/agenda/eaaci-congress-2024/

INSCRIPTIONS :
 https://eaaci.org/events_congress/eaaci-congress-2024/registration/registration/

RÉSEAUX SOCIAUX
Podcast : https://linktr.ee/eaaci
LinkedIn : https://www.linkedin.com/company/eaaci/
Instagram : @eaaciHQ
Twitter : @EAACI_HQ
Facebook : https://www.facebook.com/EAACI

CONTACT :
communications@eaaci.org

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : http://www.globenewswire.com/NewsRoom/AttachmentNg/dbb1a2e3-3aaf-442d-84ff-18369811d587

GlobeNewswire Distribution ID 1000947860

EB5 Capital Litigates USCIS’ Recent EB-5 Filing Fee Increases

WASHINGTON, April 29, 2024 (GLOBE NEWSWIRE) — On April 22, 2024, EB5 Capital, along with Invest in the USA (IIUSA), the national EB-5 trade association serving the majority of active Regional Centers, and ten other Regional Centers, filed a lawsuit against the United States Citizenship and Immigration Services (USCIS). The lawsuit, Civitas Capital Group et al. vs. USCIS et al., was filed in the District Court for the Northern District of Texas and challenges the “Final Rule” issued by the Department of Homeland Security (DHS) that concerns government filing fees for EB-5 related petitions.

The Final Rule issued by DHS on January 31, 2024, which went into effect on April 1, 2024, revised USCIS’ filing fees for all petitions and applications adjudicated by the agency. Civitas Capital Group et al. vs. USCIS et al. argues that the fee increases for EB-5 related petitions in this Final Rule are far greater both in dollar amounts and in percentage increase compared to any of the other increases in filing fees announced in this rule. “It is essential that USCIS abide by the rule of law in promulgating regulations. Its ongoing failure to do so diminishes the impact and integrity of the EB-5 Program,” commented Lulu Gordon, General Counsel for EB5 Capital. The lawsuit argues that the new fee structure violates several federal laws, including the EB-5 Reform and Integrity Act of 2022 (RIA), the Regulatory Flexibility Act (RFA), the Immigration and Nationality Act (INA), and the Administrative Procedure Act (APA), as well as internal guidelines established by the Office of Management and Budget (OMB).

“These increased fees are unreasonable and will burden our current and future investors,” said Ishaan Khanna, EB5 Capital’s Director of Business Development. Ishaan Khanna’s non-profit organization, The American Immigrant Investor Alliance (AIIA), which advocates for EB-5 investors’ rights, previously filed a similar lawsuit against USCIS in March.

For more information, a copy Civitas Capital Group et al. vs. USCIS et al. is available here.

About EB5 Capital

EB5 Capital provides qualified foreign investors with opportunities to invest in job-creating commercial real estate projects under the United States Immigrant Investor Program (EB-5 Visa Program). Headquartered in Washington, DC, EB5 Capital’s distinguished track record and leadership in the industry has attracted investors from over 75 countries. As one of the oldest and most active Regional Center operators in the country, the firm has raised over $1 billion of foreign capital across approximately 40 EB-5 projects. 100% of our investors’ funds are protected by the Federal Deposit Insurance Corporation (FDIC) insurance prior to their deployment into our projects. Please visit www.eb5capital.com for more information.  

Contact:
Katherine Willis
Director, Marketing & Communications
media@eb5capital.com

GlobeNewswire Distribution ID 9107671

Arqit announces collaboration to deliver out-of-the-box post-quantum cryptography solutions

LONDON, April 29, 2024 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, today announced the creation of the World’s First Quantum-Safe, 1.89 Tb IPsec products collaborating with Intel.

Arqit and Intel have joined forces for out-of-the-box post-quantum cryptography solutions using Arqit’s Symmetric Key Agreement Platform (SKA-Platform™) running on Intel Xeon Scalable processors. Combining Intel technologies with Arqit’s SKA-Platform™ achieves high-performance IPsec encryption, protecting against quantum attacks without compromising speed.

To find our more, join the Intel and Arqit webinar on 30th April 2024 REGISTER

David Williams, Arqit Founder, Chairman and CEO said:
“Our collaboration with Intel delivers the groundbreaking introduction of the world’s inaugural quantum-safe, 1.89 Tb IPsec solution. Cyber threats continue to become more sophisticated, including the imminent advent of quantum computing, enterprises seek robust defences. Our joint effort with Intel provides off-the-shelf products that not only harden networks but also make them quantum-safe whilst adhering to core standards like RFC 8784.”

Notes to Editors

Arqit representatives will be attending RSA (6-9 May 2024) and will be available for interview. www.rsaconference.com/usa.

Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.

About Arqit

Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit) supplies a unique encryption software service which makes the communications links of any networked device, cloud machine or data at rest secure against both current and future forms of attack on encryption – even from a quantum computer. Compatible with NSA CSfC Components and meeting the demands of NSA CSfC Symmetric Key Management Requirements Annexe 1.2. and RFC 8784, Arqit’s Symmetric Key Agreement Platform uses a lightweight software agent that allows end point devices to create encryption keys locally in partnership with any number of other devices. The keys are computationally secure and facilitate Zero Trust Network Access. It can create limitless volumes of keys with any group size and refresh rate and can regulate the secure entrance and exit of a device in a group. The agent is lightweight and will thus run on the smallest of end point devices. The product sits within a growing portfolio of granted patents. It also works in a standards compliant manner which does not oblige customers to make a disruptive rip and replace of their technology. Arqit is winner of two GSMA Global Mobile Awards, The Best Mobile Security Solution and The CTO Choice Award for Outstanding Mobile Technology, at Mobile World Congress 2024, recognised for groundbreaking innovation at the 2023 Institution of Engineering and Technology Awards and winner of the National Cyber Awards’ Innovation in Cyber Award and the Cyber Security Awards’ Cyber Security Software Company of the Year Award. Arqit is ISO 27001 Standard certified. www.arqit.uk

Media relations enquiries:
Arqit: pr@arqit.uk

Investor relations enquiries:
Arqit: investorrelations@arqit.uk
Gateway: arqit@gateway-grp.com

Caution About Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements are based on Arqit’s expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Arqit’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Arqit to predict these events or how they may affect it. Except as required by law, Arqit does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur. Uncertainties and risk factors that could affect Arqit’s future performance and cause results to differ from the forward-looking statements in this release include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against the Arqit, (ii) the ability to maintain the listing of Arqit’s securities on a national securities exchange, (iii) changes in the competitive and regulated industries in which Arqit operates, variations in operating performance across competitors and changes in laws and regulations affecting Arqit’s business, (iv) the ability to implement business plans, forecasts, and other expectations, and identify and realise additional opportunities, (v) the potential inability of Arqit to successfully deliver its operational technology, (vi) the risk of interruption or failure of Arqit’s information technology and communications system, (vii) the enforceability of Arqit’s intellectual property, and (viii) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Arqit’s annual report on Form 20-F (the “Form 20-F”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on 21 November 2023 and in subsequent filings with the SEC. While the list of factors discussed above and in the Form 20-F and other SEC filings are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realisation of forward-looking statements.

GlobeNewswire Distribution ID 9107084

‫رأس المال الخاص السعودي يركز بشكل متزايد على النمو الداخلي في عام 2024 وما بعده – تقرير Preqin

نمو عدد الصفقات الداخلية في المملكة العربية السعودية بمعدل ستة أضعاف في الفترة بين 2018 و2023

لندن, April 29, 2024 (GLOBE NEWSWIRE) —

نشرت شركة Preqin، الرائدة عالميًا في مجال البيانات والرؤى البديلة، تقريرًا بعنوان نهوض رأس المال الخاص في المملكة العربية السعودية.

يلخص التقرير إلى موضوعين رئيسيين يعززان مستقبل مكانة المملكة في مشهد رأس المال الخاص: الموضوع الأول هو تعزيز حكومة المملكة ومستثمريها وشركاتها للشراكات مع مدراء الصناديق من أجل توفير المزيد من المعارف وتطوير البنى التحتية والاستثمارات المشتركة في الدولة. ويرى مدراء الصناديق أن المملكة أصبحت الآن أكثر من مجرد موقع لجمع رأس مال المستثمرين. الموضوع الثاني هو إقبال المملكة على الاستثمارات الداخلية من خلال الأسواق الخاصة،

والتي تواصل النمو مع ريادة الأعمال الداخلية والفرص الاستثمارية.

الدور الجديد لرأس المال الخاص ومدراء الصناديق في المملكة

يحقق مشروع رؤية المملكة 2030 التي تقوده الحكومة هدف زيادة التنويع الاقتصادي والاجتماعي والثقافي في الوقت الذي تنتقل فيه المملكة لحقبة ما بعد “ذروة النفط”. وتمثل الأسواق الخاصة عنصرًا رئيسيًا لهذا الانتقال.

وعلى مدار ما يربو على 30 عامًا، أثبتت المملكة أنها واحدة من الوجهات الأكثر موثوقية لجمع رأس المال الخاص. لكن في عام 2024، ستعزز المملكة هذه العلاقة التاريخية مع مدراء الصناديق من خلال توطيد التعاون معهم بالتركيز على نشر رأس المال محليًا لتعزيز المشاريع الاقتصادية، ما يساهم في إنجاز المملكة لطموحات رؤية 2030.

لقد أدرك مدراء الصناديق أهمية استغلال مسار النمو الذي تشهده المملكة خلال السنوات الأخيرة. ففي الفترة بين 2018 ويناير 2024، تظهر بيانات Preqin أن عدد مدراء الصناديق في المملكة شهد زيادة بمعدل 213% أي ارتفع من 47 إلى 147 مدير صندوق.

الإقبال على الاستثمار الداخلي: حقوق الملكية الخاصة وصفقات رأس المال الجريء

وفي معرض تعليقه على هذه المناسبة، يقول ديفيد دوكينز، المؤلف الرئيسي للتقرير لدى Preqin: “تسعى المملكة العربية السعودية في عام 2024 بشكل متزايد إلى استخدام رأس المال الخاص لدعم فئة رواد الأعمال الناشئة في الدولة من أجل الاستعداد للحياة بعد عصر النفط. وفي سبيل المساعدة على بناء الأعمال المحلية وإيجاد فرص العمل للشباب، يسعى المستثمرون في المنطقة إلى التعاون مع مدراء المشاريع لنقل المعارف وتطوير البنية التحتية والاستثمار المشترك”.

بنهاية عام 2023، انغلقت الفجوة بشكل شبه تام بين عدد صفقات حقوق الملكية الخاصة وصفقات رأس المال الجريء التي أكملها المستثمرون السعوديون محليًا، مقارنة بالمستثمرين بالخارج. تم عقد 118 صفقة في المملكة و119 صفقة في الخارج، خلال عام 2023. وبالمقارنة، عقدت المملكة 100 صفقة حقوق ملكية خاصة ورأس مال جريء محليًا و151 صفقة بالخارج خلال عام 2022.

لقد أثبتت المملكة أنها نجم ساطع خلال “شتاء” رأس المال الجريء في الفترة من 2020 إلى 2023 حين تباطأت الصفقات على مستوى العالم. بلغت القيمة الإجمالية لصفقات رأس المال الجريء في المملكة 1.02 مليار دولار أمريكي في عام 2023، مرتفعة من 794 مليون دولار أمريكي في عام 2022.

تشمل الاستنتاجات الرئيسية الإضافية لتقرير نهوض رأس المال الخاص في المملكة العربية السعودية: دليل منطقة Preqin:

  • الاستثمارات المشتركة لرأس المال الجريء: تم عقد 47 صفقة رأسمال جريء بين مدراء الصناديق غير السعوديين والمستثمرين السعوديين في الفترة من 2018 إلى 2023. وقد تمت ثلاثة أرباع الصفقات تقريبًا، أي 34 صفقة من بين 47 صفقة في الفترة بين 2021 و2023، مما يبرز زخم هذا الاتجاه في عام 2024 وما بعده.
  • صفقات رأس المال الجريء البارزة: لقد أصبحت منصة تمارا المتخصصة في المدفوعات البنكية والتسوق، أول شركة مليارية متخصصة في التقنيات المالية بعد تأمين حصولها على 340 مليون دولار أمريكي في جولة تمويل حقوق ملكية من الفئة C في ديسمبر 2023.
  • عدد مدراء رأس المال الخاص الذين يركزون على السعودية: بنهاية عام 2021، كان هناك 131 مدير نشط يركز على نشر رأس المال في المملكة. وبحلول يناير 2024، بلغ عدد المدراء 276 مديراً، بما يمثل زيادة بنسبة 111% على مدار الفترة.

إذا كنت ترغب الحصول على مزيد من المعلومات أو إذا كنت تود التحدث إلى مؤلف التقرير، يرجى الاتصال بدون بولز على dawn.bowles@preqin.com.

نبذة عن Preqin

تُمكّن شركة Preqin، المتخصصة في الأصول البديلة Home of Alternatives™”، المهنيين الماليين الذين يستثمرون أو يكرسون أنفسهم للأصول البديلة، من خلال بيانات ورؤى أساسية لاتخاذ قرارات مستنيرة. وهي توفر الدعم لهم خلال دورة الحياة الكاملة للاستثمارات من خلال معلومات هامة وحلول تحليلية رائدة. لقد حققت الشركة الريادة في مجال الأساليب الدقيقة لجمع بيانات الخاصة على مدار 20 عامًا، بما يعمل على تمكين أكثر من 200,000 مهني على مستوى العالم لتبسيط طريقة جمعهم لرأس المال والحصول على الصفقات والاستثمارات وفهم الأداء ومداومة الاطلاع على المستجدات. لمزيد من المعلومات، يرجى زيارة www.preqin.com.

GlobeNewswire Distribution ID 1000947294